Stock market today: Stocks fall as investors rotate out of tech into Jackson Hole
TARRYTOWN, N.Y. - Medtech Products Inc., a subsidiary of Prestige Consumer Healthcare Inc. (NYSE: PBH), a $4.1 billion consumer healthcare company with strong financial health according to InvestingPro metrics, announced Tuesday a voluntary recall of five lots of Little Remedies Honey Cough Syrup due to Bacillus cereus contamination and loss of shelf-stability.
The affected products were distributed nationwide through retailers and online from December 14, 2022, through June 4, 2025. The recall includes all lots of the 4 FL OZ (118 mL) bottles still within expiry dates, specifically lot numbers 0039 (exp. 11/2025), 0545 (exp. 01/2026), 0640 (exp. 02/2026), 0450 (exp. 05/2026), and 1198 (exp. 12/2026).
Bacillus cereus can cause two types of food-borne illnesses. The first type manifests as nausea, vomiting, and stomach cramps beginning 1 to 6 hours after consumption. The second type causes stomach cramps and diarrhea starting 8 to 16 hours after consumption. While healthy individuals may experience only short-term illness, exposure to high levels of B. cereus can be fatal.
No serious adverse events have been reported to date, according to the company’s press release statement.
Consumers are advised to stop using the recalled product immediately and contact their healthcare provider if they have experienced any related health problems. The company is offering reimbursement for purchases of the affected lots.
The recall does not include any other Little Remedies products. The recall is being conducted with the knowledge of the U.S. Food and Drug Administration.
Consumers with questions can contact Medtech by email at medicalaffairs@prestigebrands.com or by phone at (800) 754-8853 Monday through Friday from 8:30 a.m. to 5:30 p.m. Eastern time.
In other recent news, Prestige Consumer Healthcare reported its fourth-quarter results for 2025, highlighting an expected revenue gain of $830 million for the year. The company also noted a significant organic revenue increase of approximately $500 million. Additionally, Prestige Consumer Healthcare has made four recent acquisitions to enhance its product offerings and plans to open a new Tennessee facility to boost production capacity. Jefferies analysts raised the price target for Prestige Brands to $85, maintaining a Hold rating, citing the company’s robust performance and strategic positioning in defensive categories. The analysts emphasized Prestige Brands’ ability to deliver stable results despite challenging market conditions. They also noted potential upsides from strategic deals and increased capital returns. Prestige Consumer Healthcare’s diversified product portfolio and strong regional brand strategy continue to differentiate it in the competitive market. The company remains focused on organic growth, particularly in the Canadian market, with a projected 2-3% organic volume growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.